TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11772282
Drug: Trimegestone 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimegestone 0.05 mg/day
Study: 9256568
Drug: Video-enhanced self-help
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video-enhanced self-help treatment manual
Study: 30242825
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg nebulized salbutamol
Study: 18173844
Drug: Lifestyle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle intervention consisting of 3 face-to-face and 4 telephone contacts over 6 months, focusing on increasing daily physical activity, improving dietary behaviour, and smoking cessation.
Study: 11446848
Drug: Acetyl‐L‐carnitine 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl‐L‐carnitine 1 g twice daily for 3 months
Study: 10569556
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg twice daily for 3 months
Study: 3052168
Drug: Propofol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2.5 mg kg‐1; n = 12)
Study: 11292011
Drug: Ayahuasca (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayahuasca (1.0 mg DMT/kg body weight)
Study: 6292981
Drug: d-amphetamine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (20 mg)
Study: 19780472
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly iron supplementation (ferrous sulphate at 200 mg)
Study: 19780472
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received once weekly vitamin C at 100 mg
Study: 16829031
Drug: Intranasally administered
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasally administered salmon calcitonin (200 IU/day)
Study: 14521703
Drug: 30% TCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% TCA solution
Study: 9382539
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion chemotherapy with CDDP + MMC +/- 5-FU (Group II)
Study: 9382539
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion chemotherapy with radiotherapy
Study: 8451057
Drug: Usual preoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual preoperative preparation provided by the physician
Study: 3530071
Drug: Stanazolol 2
Normalized name: Stanozolol
DrugBank: Stanozolol (DB06718)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stanazolol 2 mg orally 3 times a day for 30 days
Study: 27371264
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of DwPT vaccine after MMR
Study: 20660848
Drug: ASD prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASD prescription optimization protocol, patient lists for long-term ASD users, financial compensation for consultations
Study: 16298061
Drug: duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: duloxetine 60 mg QD
Study: 16298061
Drug: duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: duloxetine 60 mg BID
Study: 16298061
Drug: duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: duloxetine 60 mg QD or duloxetine 60 mg BID
Study: 11881159
Drug: Combined Treatment
Normalized name: POISON IVY/OAK/SUMAC EXTRACTS COMBINED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Treatment (PE/SIT)
Study: 31242596
Drug: Mixed spices
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed spices (5 g daily)
Study: 17126781
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of isobaric ropivacaine (group R; n = 45)
Study: 17126781
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg of isobaric bupivacaine (group B; n = 45)
Study: 16510631
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (30 mg daily)
Study: 22189527
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (30 mg daily)
Study: 16510631
Drug: Iron and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron and zinc supplementation (30 mg each daily)
Study: 1878534
Drug: Intravenous and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and/or oral doses of sodium dichloroacetate (DCA)
Study: 1878534
Drug: Oral doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doses of sodium dichloroacetate (DCA)
Study: 6193152
Drug: Intralesional bleomycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional bleomycin, 1 U/ml
Study: 15255442
Drug: Lyophilized freeze-dried
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized freeze-dried platelet derived preparation
Study: 2810163
Drug: Ilioinguinal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilioinguinal block (0.25 ml 0.5% bupivacaine/kg)
Study: 28494097
Drug: Dapsone 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone 1.5 mg/kg per day with methylprednisolone 0.5 mg/kg per day
Study: 25148377
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day fluconazole for 8 days
Study: 7676782
Drug: Eltanolone 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltanolone 0.8 mg.kg-1 (group E2)
Study: 19767384
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin pump therapy (CSII group)
Study: 18075301
Drug: 1E10 anti-idiotype
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1E10 anti-idiotype vaccine (1 mg of 1E10/Alum) administered via five bi-weekly injections followed by 10 doses at 28-day intervals.
Study: 1551720
Drug: ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ranitidine 150 mg twice daily
Study: 28870095
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human epidermal growth factor (rhEGF) spray
Study: 24998106
Drug: Morphine as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine as first analgesic medication
Study: 24998106
Drug: WHO analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: WHO analgesic ladder (non-opioids, weak opioids, strong opioids)
Study: 20538867
Drug: Spironolactone 25
Normalized name: spironolactone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25 mg per day
Study: 18800887
Drug: Honey-comparable glucose-fructose
Normalized name: fructose / glucose / phosphoric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honey-comparable glucose-fructose solution
Study: 87830
Drug: Adsorbed vaccine
Normalized name: Tetanus toxoid adsorbed vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adsorbed vaccine
Study: 23547212
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of anticitrullinated protein antibodies
Study: 8425236
Drug: Flumazenil (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.5 mg)
Study: 16765796
Drug: Vancomycin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (20 microg/mL) and gentamicin (8 microg/mL) in the infusion fluid
Study: 3596865
Drug: Ciba‐Geigy preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciba‐Geigy preparation
Study: 29288510
Drug: Treatment-as-usual (psychopharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (psychopharmacotherapy only)
Study: 24620855
Drug: Oral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral therapy with Repaglinide
Study: 1609377
Drug: Auranofin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auranofin (3 mg twice daily)
Study: 30077184
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment with ibuprofen (COXi) between 24 and 72 hours postnatal age
Study: 24549548
Drug: Citalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (10 mg per day titrated to 30 mg per day over 9 weeks)
Study: 9190324
Drug: Buprenorphine 0.6mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.6mg/day (sublingual)
Study: 3117236
Drug: somatrem (methionyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: somatrem (methionyl growth hormone)
Study: 26495319
Drug: Propofol (target-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (target-controlled infusion)
Study: 19211665
Drug: After 12-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: After 12-week treatment
Study: 29798336
Drug: Radiotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy and chemotherapy combined with cetuximab
Study: 17941869
Drug: Diet alone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet alone, diet followed by metformin, or metformin alone
Study: 15852991
Drug: Melatonin 0.5
Normalized name: melatonin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 0.5 mg kg(‐1)
Study: 15852991
Drug: Midazolam 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.25 mg kg(‐1)
Study: 22315765
Drug: Midazolam 0.5
Normalized name: midazolam 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.5 mg kg(‐1)
Study: 29695183
Drug: Bacillus coagulans
Normalized name: Bacillus coagulans
DrugBank: Bacillus coagulans (DB19246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus coagulans Unique IS2 chewable tablets
Study: 27040087
Drug: Testosterone (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (intramuscular injection of testosterone undecylate for 4 months)
Study: 11134978
Drug: Black currant
Normalized name: Black currant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black currant anthocyanosides (BCA) 50 mg/subject
Study: 1397814
Drug: Home visits
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home visits focusing on smoking, drug and nutrition education, support, and links with community services
Study: 20602712
Drug: Tapentadol ER
Normalized name: tapentadol Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol ER (100 to 250 mg bid)
Study: 20602712
Drug: Oxycodone CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone CR (20 to 50 mg bid)
Study: 18047650
Drug: Manual therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy, exercise and advice without traction
Study: 7892983
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy for 24 hours followed by continuation for 3 days (Group 1)
Study: 7892983
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy for 3 days (Group 3)
Study: 7892983
Drug: No oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oxygen therapy (Group 4)
Study: 3034541
Drug: CMV hyperimmunoglobulin
Normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV hyperimmunoglobulin (CMV-Polyglobin) administered intravenously at 2 ml/kg bodyweight at three-week intervals up to day 105 after kidney transplantation
Study: 9787686
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no infusions)
Study: 1097478
Drug: Penfluridol, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penfluridol, administered in a dosage of 40 to 80 mg once a week
Study: 1097478
Drug: Neuroleptics requiring
Normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptics requiring daily administration
Study: 31470091
Drug: Stereotactic Ablative
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic Ablative Radiation Therapy (SABR)
Study: 24274342
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment including therapeutic hypothermia initiated after hospital admission
Study: 21555501
Drug: CLON‐XR plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLON‐XR plus stimulant
Study: 21555501
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus stimulant
Study: 19002433
Drug: Omega-3 EE90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 EE90 (2 g/day)
Study: 9109229
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy given preoperatively
Study: 9109229
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy and chemotherapy given preoperatively
Study: 8197612
Drug: 2x 100
Normalized name: Ryna-12X 100mg-5mg-30mg/5ml Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2x 100 mg/day CsA from day 0
Study: 8197612
Drug: 2x 200
Normalized name: Hytuss 2X 200 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2x 200 mg/day CsA from day 4
Study: 3070179
Drug: Intramuscular emulsified
Normalized name: diazepam
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular emulsified disulfiram
Study: 25048646
Drug: Nondrug, nonoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nondrug, nonoperative interventions (e.g., weight loss, shoe orthoses)
Study: 21804624
Drug: Routine preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine preparation for venipuncture (Control group)
Study: 26699899
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no statin treatment)
Study: 16595583
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (CC) during the whole study period (3 years)
Study: 3370063
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg i.v. over 1 h
Study: 3370063
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg p.o.
Study: 29089192
Drug: Anti-staphylococcal vaccine
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-staphylococcal vaccine
Study: 6117682
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no vaccine)
Study: 25837193
Drug: Ropivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine plus 5 μg of sufentanil (group RS)
Study: 16544586
Drug: Cluster up-dosing
Normalized name: cluster fig extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cluster up-dosing scheme (3 weeks duration, 19 patients)
Study: 16544586
Drug: Traditional up-dosing
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional up-dosing scheme (13 weeks duration, 19 patients)
Study: 16544586
Drug: Cluster up-dosing
Normalized name: cluster fig extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cluster up-dosing scheme
Study: 12727580
Drug: Estrogen/progestin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen/progestin therapy (17beta-estradiol [1 mg/d] combined with norethisterone acetate [0.5 mg/d])
Study: 2856903
Drug: Oxmetidine, 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxmetidine, 600 mg bedtime
Study: 31246796
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine (266 mg)
Study: 31246796
Drug: Conventional bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional bupivacaine (75 mg)
Study: 17684364
Drug: DIC 75
Normalized name: DIC
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DIC 75 mg/day plus GGA 150 mg/day for 2 weeks
Study: 17684364
Drug: DIC 75
Normalized name: DIC
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DIC 75 mg/day plus placebo (lactose 1.5 g/day) for 2 weeks
Study: 86665
Drug: medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: medical treatment
Study: 25464680
Drug: Electro acupuncture
Normalized name: ELECTRODE SPRAY,ELECTRO MIST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electro acupuncture therapy (10 sittings over 30 days)
Study: 25464680
Drug: Conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drug therapy (oral flunarizine 20 mg OD and paracetamol 500 mg SOS for 30 days)
Study: 9650124
Drug: Theophylline (165
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (165 mg)
Study: 3378856
Drug: Tizanidine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tizanidine 3 mg
Study: 3378856
Drug: Tizanidine 6
Normalized name: tizanidine 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tizanidine 6 mg
Study: 29227845
Drug: Pill placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill placebo during 12-session exposure-based group CBT
Study: 29129190
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) protocol for AUD, sessions five and six of a 12-session protocol
Study: 24569031
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of bone marrow-derived cells (BMCs)
Study: 17261891
Drug: Blueberin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blueberin (300 mg, 3 times per day for 4 weeks)
Study: 13129472
Drug: Capsaicin (135
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin (135 mg capsaicin/d)
Study: 1349757
Drug: Fluspirilene (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluspirilene (0.5, 1.0, or 1.5 mg per week)
Study: 1349757
Drug: Fluspirilene (max
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluspirilene (max 1.5 mg/week)
Study: 27181277
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy group (IT group; n = 22) - combined moderate intensity aerobic and resistance training three times per week for 12 weeks
Study: 27181277
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy group (CT group; n = 20) - metformin and diet control
Study: 18633048
Drug: parecoxib 20
Normalized name: parecoxib 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: parecoxib 20 mg bid
Study: 18633048
Drug: parecoxib 20
Normalized name: parecoxib 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: parecoxib 20 mg qd
Study: 12354679
Drug: Multivitamin-multimineral supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin-multimineral supplementation (VITALIA-tablets)
Study: 10192755
Drug: Fluvoxamine 50
Normalized name: fluvoxamine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine 50 mg as a single oral dose
Study: 10192755
Drug: Caffeine 200
Normalized name: caffeine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 200 mg as a single oral dose
Study: 2197382
Drug: Rectal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rectal midazolam 0.45 mg/kg
Study: 6117434
Drug: Oral ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ranitidine administration
Study: 6117434
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg body wt ranitidine infusion
Study: 28124736
Drug: High flow
Normalized name: Blood Set High Flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flow nasal cannula (HFNC) at 2 L/kg/min oxygen therapy
Study: 26103129
Drug: Control (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (4 g olive oil daily for 8 weeks)
Study: 25816050
Drug: Rosuvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (40 mg/d)
Study: 17106937
Drug: CIFN in
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIFN in combination with ribavirin
Study: 19608530
Drug: Valacyclovir 500
Normalized name: valacyclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 500 mg once daily
Study: 11724461
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment (specific dietary fatty acids not detailed)
Study: 8020175
Drug: Prophylactic ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic ceftriaxone administration (Group A)
Study: 8020175
Drug: Other antibiotics
Normalized name: Other antibiotics for topical use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antibiotics (Group C)
Study: 8020175
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics (Group D)
Study: 8020175
Drug: Prophylactic ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic ceftriaxone administration (Group A) - Newborns
Study: 31812890
Drug: Alectinib 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alectinib 300 mg twice daily
Study: 24102964
Drug: Low-dose dobutamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dobutamine (10 μg/kg per min)
Study: 17323592
Drug: Clopidogrel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel plus Aspirin (dual antiplatelet therapy)
Study: 27423556
Drug: Aspirin (monotherapy)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (monotherapy)
Study: 10923282
Drug: Drospirenone alone
Normalized name: Drospirenone
DrugBank: Drospirenone (DB01395)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drospirenone alone (0.5-3.0 mg/day for one cycle)
Study: 10923282
Drug: Ethinylestradiol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinylestradiol (30 micrograms) + Drospirenone (2 mg or 3 mg for three cycles)
Study: 10923282
Drug: Ethinylestradiol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinylestradiol (30 micrograms) + Drospirenone (3 mg)
Study: 15965309
Drug: Entacapone 200
Normalized name: entacapone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entacapone 200 mg